Using Wegovy: what actually happens week by week

How does the dose schedule actually work when you begin?

The dose you start on is not the dose that does the heavy lifting. Wegovy begins at 0.25mg weekly — a level chosen specifically to let your digestive system settle before the dose climbs. Your prescriber will typically step this up through 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg, spending roughly a month at each level. Since April 2026 the MHRA has also approved a 7.2mg maximum dose, delivered via a dedicated single-dose pen, for adults with a BMI of 30 or above; the titration journey to that level follows the same staged approach.

The pacing matters. Rushing through dose increases is one of the things our prescribers hear patients ask about most, the temptation to move faster is understandable when you want results. But the gradual schedule exists to keep side effects manageable, and skipping rungs tends to amplify nausea rather than speed progress. If a dose increase feels too uncomfortable, your prescriber can hold the current level longer before going up.

Injection sites rotate between the abdomen, thigh and upper arm. The pen itself is pre-filled; you change the needle for each injection and dispose of used needles safely. For specific storage temperatures and the exact room-temperature window your pen allows, the Wegovy SmPC on the eMC has the definitive detail, it is worth reading before your first dose.

What does using Wegovy actually feel like in the first few months?

The honest answer is that it varies. A common misconception is that Wegovy switches off hunger completely from week one, that is not quite how it works. For most people, the change is more like a gradual dimmer switch than a hard stop: portions that used to feel normal start to feel like too much, and the drive to snack between meals quietly fades. That shift tends to deepen as the dose increases.

Nausea is the side effect people ask about most, and it is real. It is usually most noticeable in the day or two after an injection, particularly after each dose increase, and it typically settles within a couple of weeks at the new level. Eating smaller meals, avoiding very fatty or rich food around injection day, and staying well hydrated all help. Constipation catches some people off guard, fibre and fluid intake become more important, not less, when your appetite is reduced.

The NHS semaglutide medicines page lists all known side effects clearly and is a useful reference to bookmark alongside your Patient Information Leaflet. If you experience severe or persistent stomach pain that spreads toward your back, seek medical advice promptly, this is one of the warning signs for pancreatitis, which the MHRA flagged in a 2026 Drug Safety Update as an infrequent but serious risk with GLP-1 medicines.

Who can and cannot use Wegovy in practice?

The licensed eligibility criteria give a starting point: adults with a BMI of 30 or above, or 27 and above alongside at least one relevant condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. But eligibility in practice is broader than a single number, a prescriber looks at your full medical picture, including other medicines you take and any personal or family history of conditions such as pancreatitis, thyroid cancer or inflammatory bowel disease.

Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. It is not licensed for under-18s. Women taking the oral contraceptive pill alongside tirzepatide (a different GLP-1 medicine) need additional contraception, though current evidence does not show the same absorption concern for semaglutide, the active ingredient in Wegovy, your prescriber will advise based on your specific situation. If you are exploring how Wegovy supports weight loss more broadly, that page covers the evidence in more depth.

Transfer patients (people switching from another GLP-1 medicine or another provider) are welcome at our pharmacy, but a full clinical review still takes place before treatment continues. The same applies to any dose increase: evidence of where you currently are is part of that process.

What happens beyond the injection itself, lifestyle, support and what to expect long term?

Wegovy is licensed as an add-on to a reduced-calorie diet and increased physical activity, and that framing is deliberate. The medicine does a lot of the appetite work, but protein intake matters more on a reduced-calorie plan (muscle loss is a real risk if food quality drops), and some form of resistance activity helps preserve lean mass. These are not optional extras, they are part of what makes the results durable.

The STEP 1 trial, which followed adults for 68 weeks, found an average weight reduction of around 15% at the 2.4mg maintenance dose. Those results were achieved alongside lifestyle changes, not in isolation. Practical tips for getting the most from Wegovy covers the day-to-day habits that tend to make a real difference.

Questions about when and how to stop Wegovy come up regularly too, particularly after people read about weight returning after treatment ends. The current evidence does suggest gradual weight regain is common after stopping, which is why any decision about duration is made with a prescriber rather than arbitrarily. Whether stopping is right for you is a conversation worth having before you reach that point. If you would like to understand your treatment options and check your eligibility, our prescribers are available the same day. For a full walkthrough of how to prepare and administer your injections correctly, our guide to using semaglutide safely and effectively is a good place to start.